HHS Secretary Alex Azar Talks Rebate Changes, But Not Eliminating Discounts Altogether
Executive Summary
Details on anticipated changes to rebate practices are in demand. HHS Secretary Azar talked about changes that would still allow negotiated discounts at the point of sale during a presentation at the FT Pharma Pricing and Value Summit.
You may also be interested in...
Making Real World Evidence Less 'Messy' To Help With Drug Pricing
The Medicines Company's inclisirin CV trial is 100-fold cheaper with digitized records, while Lilly is still hunting for a good HBA1C dataset, and Merck worries about "idiosyncratic" data.
Value-Based Payment Experiments For Drugs To Be Key Focus For CMMI, Director Says
Recently-installed Center for Medicare and Medicaid Innovation Chief Adam Boehler says payment lab will play a role in the Administration’s overall approach to lowering prescription drug costs.
HHS Advancing Attack On Rebates With Proposal To Revoke Safe Harbor
Upcoming proposed rule could also provide new anti-kickback safe harbor to facilitate value-based contracts, as manufacturers and payers have urged.